TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F21%3A00542897" target="_blank" >RIV/61388971:_____/21:00542897 - isvavai.cz</a>
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1889822" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/2162402X.2021.1889822</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/2162402X.2021.1889822" target="_blank" >10.1080/2162402X.2021.1889822</a>
Alternative languages
Result language
angličtina
Original language name
TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
Original language description
Accumulating evidence indicates that immune checkpoint inhibitors (ICIs) can restore CD8(+) cytotoxic T lymphocyte (CTL) functions in preclinical models of acute myeloid leukemia (AML). However, ICIs targeting programmed cell death 1 (PDCD1, best known as PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4) have limited clinical efficacy in patients with AML. Natural killer (NK) cells are central players in AML-targeting immune responses. However, little is known on the relationship between co-inhibitory receptors expressed by NK cells and the ability of the latter to control AML. Here, we show that hepatitis A virus cellular receptor 2 (HAVCR2, best known as TIM-3) is highly expressed by NK cells from AML patients, correlating with improved functional licensing and superior effector functions. Altogether, our data indicate that NK cell frequency as well as TIM-3 expression levels constitute prognostically relevant biomarkers of active immunity against AML.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10606 - Microbiology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Oncoimmunology
ISSN
2162-402X
e-ISSN
2162-402X
Volume of the periodical
10
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
13
Pages from-to
1889822
UT code for WoS article
000627790900001
EID of the result in the Scopus database
2-s2.0-85102181179